Cargando…
Impact of night-time symptoms in COPD: a real-world study in five European countries
BACKGROUND: Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD). A cross-sectional European survey investigated the prevalence of night-time symptoms in COPD to evaluate the level of disconnect between physician and patient perceptions of the presence of night-t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849086/ https://www.ncbi.nlm.nih.gov/pubmed/24348032 http://dx.doi.org/10.2147/COPD.S48570 |
_version_ | 1782293875835011072 |
---|---|
author | Price, David Small, Mark Milligan, Gary Higgins, Victoria Gil, Esther Garcia Estruch, Jordi |
author_facet | Price, David Small, Mark Milligan, Gary Higgins, Victoria Gil, Esther Garcia Estruch, Jordi |
author_sort | Price, David |
collection | PubMed |
description | BACKGROUND: Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD). A cross-sectional European survey investigated the prevalence of night-time symptoms in COPD to evaluate the level of disconnect between physician and patient perceptions of the presence of night-time symptoms, and to compare the characteristics of patients with and without night-time symptoms. METHODS: A total of 251 primary care physicians and 251 respiratory specialists completed record forms on 2,807 patients with COPD. The forms captured information on patient demographics, lung function, COPD severity, and symptoms. Patients completed questionnaires on the time of day when their COPD symptoms bothered them, and the impact of COPD on their ability to get up in the morning and on sleep. Data were compared between groups (those with and without night-time symptoms) using t-tests or Wilcoxon signed rank tests. The kappa statistic was used to assess the level of disconnect between physician and patient perceptions of the impact of night-time symptoms. RESULTS: Most patients (78%) reported night-time disturbance. Patients with night-time symptoms experienced more daytime breathlessness (mean modified Medical Research Council dyspnea scale score 2.4 versus 1.1) and exacerbations in the previous 12 months (mean 1.7 versus 0.4), and received more maintenance therapy (mean of 2.8 versus 2.3 products) than those without. Concordance between the frequency of physician-reported (67.9% of patients) and patient-reported (68.5% of patients) night-time symptoms was good. Physicians significantly underestimated the impact of COPD on the patient’s ability to get up in the morning and on sleep (fair–moderate agreement). Physician-reported night-time symptoms were present for 41.2% of patients who could be categorized by Global initiative for chronic Obstructive Lung Disease (GOLD) group (n=937), increasing from 20.9% of those in the low-risk group to 77.4% of those in the high-riskgroup. CONCLUSION: Patients with COPD experience night-time symptoms regardless of GOLD group, that impact on their ability to get up in the morning and on their sleep quality. |
format | Online Article Text |
id | pubmed-3849086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38490862013-12-13 Impact of night-time symptoms in COPD: a real-world study in five European countries Price, David Small, Mark Milligan, Gary Higgins, Victoria Gil, Esther Garcia Estruch, Jordi Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD). A cross-sectional European survey investigated the prevalence of night-time symptoms in COPD to evaluate the level of disconnect between physician and patient perceptions of the presence of night-time symptoms, and to compare the characteristics of patients with and without night-time symptoms. METHODS: A total of 251 primary care physicians and 251 respiratory specialists completed record forms on 2,807 patients with COPD. The forms captured information on patient demographics, lung function, COPD severity, and symptoms. Patients completed questionnaires on the time of day when their COPD symptoms bothered them, and the impact of COPD on their ability to get up in the morning and on sleep. Data were compared between groups (those with and without night-time symptoms) using t-tests or Wilcoxon signed rank tests. The kappa statistic was used to assess the level of disconnect between physician and patient perceptions of the impact of night-time symptoms. RESULTS: Most patients (78%) reported night-time disturbance. Patients with night-time symptoms experienced more daytime breathlessness (mean modified Medical Research Council dyspnea scale score 2.4 versus 1.1) and exacerbations in the previous 12 months (mean 1.7 versus 0.4), and received more maintenance therapy (mean of 2.8 versus 2.3 products) than those without. Concordance between the frequency of physician-reported (67.9% of patients) and patient-reported (68.5% of patients) night-time symptoms was good. Physicians significantly underestimated the impact of COPD on the patient’s ability to get up in the morning and on sleep (fair–moderate agreement). Physician-reported night-time symptoms were present for 41.2% of patients who could be categorized by Global initiative for chronic Obstructive Lung Disease (GOLD) group (n=937), increasing from 20.9% of those in the low-risk group to 77.4% of those in the high-riskgroup. CONCLUSION: Patients with COPD experience night-time symptoms regardless of GOLD group, that impact on their ability to get up in the morning and on their sleep quality. Dove Medical Press 2013 2013-11-27 /pmc/articles/PMC3849086/ /pubmed/24348032 http://dx.doi.org/10.2147/COPD.S48570 Text en © 2013 Price et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Price, David Small, Mark Milligan, Gary Higgins, Victoria Gil, Esther Garcia Estruch, Jordi Impact of night-time symptoms in COPD: a real-world study in five European countries |
title | Impact of night-time symptoms in COPD: a real-world study in five European countries |
title_full | Impact of night-time symptoms in COPD: a real-world study in five European countries |
title_fullStr | Impact of night-time symptoms in COPD: a real-world study in five European countries |
title_full_unstemmed | Impact of night-time symptoms in COPD: a real-world study in five European countries |
title_short | Impact of night-time symptoms in COPD: a real-world study in five European countries |
title_sort | impact of night-time symptoms in copd: a real-world study in five european countries |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849086/ https://www.ncbi.nlm.nih.gov/pubmed/24348032 http://dx.doi.org/10.2147/COPD.S48570 |
work_keys_str_mv | AT pricedavid impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries AT smallmark impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries AT milligangary impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries AT higginsvictoria impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries AT gilesthergarcia impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries AT estruchjordi impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries |